2.3.0 IPECAD open-source model

This version has been developed related to the manuscript found here: Handels et al. [2024] https://doi.org/10.1016/j.jval.2024.07.009. In this manuscript we describe the new IPECAD open-source model framework (version 2) for the health-economic evaluation of early AD treatment and aim to apply it in 3 use cases for AD lecanemab treatment:

1. Cross-validating an existing model with a similar structure.
2. Cross-validating an existing model with a more complex structure.
3. Assessing additional uncertainty scenarios.

2.2.0 IPECAD workshop cross-comparison 2023 SveDem

This version is used for the IPECAD workshop model cross-comparison 2023. These results have been used for:

• the poster at ISPOR 2023: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/131246 and https://ipecadgroup.wordpress.com/workshop/
• manuscript submitted to Value in Health in 2024 entitled "IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease"

This version has been developed by:
Ron Handels
Anders Wimo

2.1.0 ISPOR Europe 2023 abstract

This version reproduces the results of the abstract submitted for review to ISPOR Europe 2023 conference.